Genocea Biosciences (GNCA) Tops Q4 EPS by 12c; Announces Diantha Duvall as New CFO

Genocea Biosciences (NASDAQ: GNCA) reported Q4 EPS of $0.00, $0.12 better than the analyst estimate of ($0.12).

“We are very pleased to welcome Diantha to Genocea,” said Chip Clark, president & CEO of Genocea. “She joins us at a truly exciting time. With our recently completed equity financing and advancing pipeline, we look forward to an eventful 2019. We foresee important near-term milestones in two programs, each driven by our unique ATLAS™ neoantigen identification platform: first, our Phase 1/2a clinical program for our neoantigen cancer vaccine candidate, GEN-009, from which we expect to see the first immunogenicity data in mid-2019, and second, our GEN-011 program, a neoantigen adoptive T cell therapy, for which we plan to file an IND in the first half of 2020.”

Guidance

Genocea expects that its existing cash and cash equivalents are sufficient to support its operations into the first quarter of 2020.

For earnings history and earnings-related data on Genocea Biosciences (GNCA) click here.

You May Also Be Interested In

• Optimum Communications gets NYSE non-compliance notice over stock price
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c